Johan Färnstrand has been appointed new Director General of the trade association for the research-based pharmaceutical industry in Sweden.

Färnstrand will start his new position on March 1st, succeeding Anders Blanck who leaves Lif at his own request after 11 years as Director General.

Johan Färnstrand

Johan Färnstrand has during the last couple of years been the head of Aleris’ Swedish healthcare activities and the CEO of Aleris Sjukvård AB. He has previously been Regional Director in Gävleborg and before that he has held leading positions within Uppsala kommun, the media industry and at SAS, as well as several board assignments within different industries. He has studied Business Administration at Uppsala University and holds an MBA from Stockholm School of Economics.

“This is an exciting challenge at an eventful time, and at the same time I am humbled by the task. The industry is completely central to the development of the healthcare sector, and developments within medical innovation and precision medicine implies that we are facing a paradigm shift, but we are at the same time facing challenges when new effective treatments are not reaching the patients, where they bring real benefit. I look forward to the opportunity to continue to develop Swedish healthcare, but now from a new perspective,” says Johan Färnstrand.

Photo of Johan Färnstrand: Lif